iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024
April 03, 2024 04:00 ET
|
iOmx Therapeutics AG
OMX-0407: clinical-stage, spectrum selective SIK kinase inhibitor with dual effect on tumor growth and immune evasionIOMX-0675: best-in-class antibody targeting immunosuppressive receptors LILRB1...